Vicor Technologies, Inc. (VCRT.OB) Receives Approval for PD2i® Testing
Vicor Technologies, Inc., a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software, announced today that it has received Institutional Review Board (IRB) approval for a study to identify normal ranges for the PD2i® values from tests performed with its PD2i Analyzer™. In collaboration with the University of Mississippi, this study will be performed on patients at rest and in response to controlled exercises and paced respirations done. David H. Fater, CEO of Vicor Technologies, Inc. commented, “We’re pleased to have IRB approval permitting us to commence this important…